These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 27839981

  • 1. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
    Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Cooper PA, Varughese S, Giraldo P, Petakov M, Tan ES, Chertkoff R.
    Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
    [Abstract] [Full Text] [Related]

  • 2. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A.
    Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
    [Abstract] [Full Text] [Related]

  • 3. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM, Shankar SP, Petakov M, Giraldo P, Rosenbaum H, Amato DJ, Szer J, Chertkoff R, Brill-Almon E, Zimran A.
    Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
    Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, Elstein D, Paz A, Brill-Almon E, Chertkoff R.
    Blood Cells Mol Dis; 2015 Jan; 54(1):9-16. PubMed ID: 25453586
    [Abstract] [Full Text] [Related]

  • 5. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
    Zimran A, Durán G, Giraldo P, Rosenbaum H, Giona F, Petakov M, Terreros Muñoz E, Solorio-Meza SE, Cooper PA, Varughese S, Alon S, Chertkoff R.
    Blood Cells Mol Dis; 2019 Sep; 78():14-21. PubMed ID: 27499018
    [Abstract] [Full Text] [Related]

  • 6. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
    Zimran A, Wajnrajch M, Hernandez B, Pastores GM.
    Orphanet J Rare Dis; 2018 Feb 23; 13(1):36. PubMed ID: 29471850
    [Abstract] [Full Text] [Related]

  • 7. Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease.
    Zimran A, Durán G, Mehta A, Giraldo P, Rosenbaum H, Giona F, Amato DJ, Petakov M, Muñoz ET, Solorio-Meza SE, Cooper PA, Varughese S, Chertkoff R, Brill-Almon E.
    Am J Hematol; 2016 Jul 23; 91(7):656-60. PubMed ID: 27174694
    [Abstract] [Full Text] [Related]

  • 8. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, Cox TM.
    Cochrane Database Syst Rev; 2015 Mar 27; 2015(3):CD010324. PubMed ID: 25812601
    [Abstract] [Full Text] [Related]

  • 9. Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
    Kuter DJ, Wajnrajch M, Hernandez B, Wang R, Chertkoff R, Zimran A.
    Blood Cells Mol Dis; 2020 May 27; 82():102418. PubMed ID: 32146279
    [Abstract] [Full Text] [Related]

  • 10. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 27; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul 27; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 12. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb 27; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 13. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, Tiomkin M, Zimran A.
    Blood Cells Mol Dis; 2012 Jan 15; 48(1):45-50. PubMed ID: 22047948
    [Abstract] [Full Text] [Related]

  • 14. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
    Cravo R, Rotman V, Oliveira PMN, Defendi HGT, Conceição DA, Xavier JR, Chertkoff R, Noronha TG, Maia MLS.
    Blood Cells Mol Dis; 2018 Feb 15; 68():160-162. PubMed ID: 28131618
    [Abstract] [Full Text] [Related]

  • 15. Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology.
    Grabowski GA, Golembo M, Shaaltiel Y.
    Mol Genet Metab; 2014 May 15; 112(1):1-8. PubMed ID: 24630271
    [Abstract] [Full Text] [Related]

  • 16. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A.
    Am J Hematol; 2013 Mar 15; 88(3):179-84. PubMed ID: 23400823
    [Abstract] [Full Text] [Related]

  • 17. Safety and effectiveness of taliglucerase alfa in patients with Gaucher disease: an interim analysis of real-world data from a multinational drug registry (TALIAS).
    Titievsky L, Schuster T, Wang R, Younus M, Palladino A, Quazi K, Wajnrajch MP, Hernandez B, Becker PS, Weinreb NJ, Chambers C, Mansfield R, Taylor L, Tseng LJ, Kaplan P.
    Orphanet J Rare Dis; 2022 Apr 01; 17(1):145. PubMed ID: 35365177
    [Abstract] [Full Text] [Related]

  • 18. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ, Camelo JS, Charrow J, McClain MR, Mistry P, Belmatoug N, International Collaborative Gaucher Group (ICGG) Gaucher Registry (NCT00358943) investigators.
    Mol Genet Metab; 2021 Feb 01; 132(2):100-111. PubMed ID: 33485799
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of Novel Plant Cell-Expressed Taliglucerase Alfa in Adult and Pediatric Patients with Gaucher Disease.
    Abbas R, Park G, Damle B, Chertkoff R, Alon S.
    PLoS One; 2015 Feb 01; 10(6):e0128986. PubMed ID: 26053270
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
    Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA.
    Am J Hematol; 2013 Mar 01; 88(3):172-8. PubMed ID: 23339116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.